Covid-19: Clinical Trials to Start on Colchicine by Hannah Joy on June 14, 2021 at 1:47 PM
Colchicine drug is gonna undergo a two-arm phase-II clinical trial by the Council of Scientific and Industrial Research (CSIR) to assess the safety and efficacy of the drug in treating Covid-19.
Colchicine is used for treating gout and related inflammatory conditions. The drug is expected to be an important therapeutic intervention for Covid patients with cardiac co-morbidities.
A number of global studies have confirmed now that cardiac complications during course of Covid-19 infections and post-Covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs.
Clinical trial to test mix-and-match of Covid vaccine boosters has begun by the US researchers. This research will help us understand if adults who have been fully vaccinated with one type of Covid-19 vaccine can receive booster doses of a different Covid-19 vaccine or not.
Update on Phase III Trial of AKP02 for Treating Psoriasis medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.
New COVID Vaccine for Clinical Trials Approved by Colleen Fleiss on April 12, 2021 at 10:16 PM
China s Sinopharm COVID-19 vaccine has recently been approved for clinical trials.
The new recombinant Covid-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D centre of Sinopharm s bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday, Xinhua reported.
It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralising antibodies.
‘The COVID-19 vaccine is based on the structural features of the receptor binding domain (RBD) on the virus spike protein (S-protein).’
Are Healthy People Infected With Covid-19 for Clinical Trials Being Paid? by Hannah Joy on February 6, 2021 at 1:17 PM
Healthy people volunteering to be infected with SARS-CoV-2 should receive a substantial amount, as they are helping scientists to better understand how to tackle the virus.
Those are the findings of a new peer-reviewed study published in the American Journal of Bioethics, which has assessed the ethics of paying participants to take part in so-called Human Infection Challenge Studies (HICS).
Over the past few months there has been vast media coverage and discussion about the first COVID-19 HICS in the world, planned to begin in the UK later this year. This type of study can be particularly valuable for testing vaccines and can speed up the development of new vaccines.